Year-end Sale % OFF 
Abstract
Glioma is one of the most common malignant tumors of the central nervous system, and its prognosis is extremely poor. Aberrant methylation of lncRNA promoter region is significantly associated with the prognosis of glioma patients. In this study, we investigated the potential impact of methylation of lncRNA promoter region in glioma patients to establish a signature of nine lncRNA methylated genes for determining glioma patient prognosis. Methylation data and clinical follow-up data were obtained from The Cancer Genome Atlas (TCGA). The multistep screening strategy identified nine lncRNA methylated genes that were significantly associated with the overall survival (OS) of glioma patients. Subsequently, we constructed a risk signature that containing nine lncRNA methylated genes. The risk signature successfully divided the glioma patients into high-risk and low-risk groups. Compared with the low-risk group, the high-risk group had a worse prognosis, higher glioma grade, and older age. Furthermore, we identified two lncRNAs termed PCBP1-AS1 and LINC02875 that may be involved in the malignant progression of glioma cells by using the TCGA database. Loss-of-function assays confirmed that knockdown of PCBP1-AS1 and LINC02875 inhibited the proliferation, migration, and invasion of glioma cells. Therefore, the nine lncRNA methylated genes signature may provide a novel predictor and therapeutic target for glioma patients.
Highlights
Glioma is the most common primary malignant tumor of the central nervous system
Epigenetics mainly involves the modification of DNA or proteins and posttranslational modification of histone proteins, and its function in the occurrence, malignant progression, and prognosis of gliomas has been demonstrated [37, 38]
Through whole-genome DNA methylation analysis, researchers can distinguish the malignant degree of gliomas and predict the prognosis of patients [40, 41]
Summary
Glioma is the most common primary malignant tumor of the central nervous system. glioma has a high recurrence rate, high mortality rate, and low cure rate [1]. The World Health Organization (WHO) classifies glioma cells into four types according to their morphological characteristics and prognosis [2]. Based on the current classification of glioma grade, it is no longer possible to accurately predict the survival and prognosis of patients. Exploration of new molecular biomarkers related to the pathogenesis of glioma may benefit the diagnosis and treatment of glioma with different grades. Molecular studies could provide new biomarkers for the heterogeneity of glioma cells, predict the treatment sensitivity and survival time of different patients, and enable lncRNA Methylated Genes Predict Survival patients to obtain treatment benefits and maximize survival time. It is necessary to find a new classification method to classify glioma and predict the prognosis of patients based on the original histological classification system
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
